
- April 2016 Respiratory Health
- Volume 82
- Issue 4
Rx Product News (April 2016)
Read about the new Rx Products featured in April.
Pharmacyclics, Inc
Indication: The FDA has approved Imbruvica (ibrutinib), a kinase inhibitor, for treatment-naïve patients with chronic lymphocytic leukemia. For the recommended dosage, see the full prescribing information. Capsules should be taken orally with a glass of water and should not be opened, broken, or chewed. There are no contraindications for use.
Dosage Form: Capsules: 140 mg
For More Information: imbruvica.com
Dexilant SoluTabMarketed by: Takeda Pharmaceuticals
Indication: The FDA has approved Dexilant SoluTab (dexlansoprazole) for the following uses in adults:
- Maintaining healing of erosive esophagitis and relief of heartburn
- Treating heartburn associated with gastroesophageal reflux disease
For the recommended dosages, see the full prescribing information.
Dosage Form: Delayed-release orally disintegrating tablets: 30 mg
For More Information: takeda.us/products
Onzetra XsailMarketed by: Avanir Pharmaceuticals, Inc
Indication: The FDA has approved Onzetra Xsail (sumatriptan nasal powder), a serotonin 5-HT1B/1D receptor agonist (triptan), for acute treatment of migraine with or without aura in adults. The recommended dose is 22 mg, administered by use of 1 nosepiece (11 mg) in each nostril. The maximum dose in a 24-hour period should not exceed 2 doses (44 mg) separated by at least 2 hours.
Dosage Form: Capsule in disposable nosepiece: 11 mg sumatriptan as the succinate salt; for use with the Xsail breath-powered delivery device only
For More Information: onzetra.com
EmendMarketed by: Merck & Co, Inc
Indication: The FDA has approved Merck’s supplemental new drug application for Emend (single-dose fosaprepitant dimeglumine) for injection. Emend, a substance P/ neurokinin 1 receptor antagonist, is indicated for managing acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy, including high-dose cisplatin; nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy; and, in adults, prevention of postoperative nausea and vomiting.
Dosage Form: Injection: 150 mg in a single-use vial
For More Information: merck.com
Articles in this issue
almost 10 years ago
Total Store Expo 2016 Promises Tremendous Opportunityalmost 10 years ago
Correcting Bad Work Habitsalmost 10 years ago
Can You Read These Rxs? (April 2016)almost 10 years ago
Compassionate Carealmost 10 years ago
Case Studies (April 2016)almost 10 years ago
Pet Peeves (April 2016)almost 10 years ago
Comparative Study of Tinzaparin to Warfarin Yields Mixed FindingsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

























